Hyundai ADM Bio Inc. (KOSDAQ:187660)

Market Cap	508.20B +369.6%
Revenue (ttm)	9.74B -29.3%
Net Income	-20.10B
EPS	-475.02
Shares Out	54.76M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	32,895,290
Average Volume	15,230,022
Open	8,400.00
Previous Close	n/a
Day's Range	8,000.00 - 9,590.00
52-Week Range	1,118.00 - 9,590.00
Beta	1.11
RSI	92.20
Earnings Date	Mar 16, 2026

About Hyundai ADM Bio

Hyundai ADM Bio Inc., a contract research organization, provides clinical services in Asia. It offers clinical development services, such as medical writing, clinical operation, late phase study, data management, biostatistics, and regulatory affairs. The company also provides pharmacovigilance services, which include case processing and safety reporting, safety and risk management plans, aggregate reporting, literature screening, and medical device vigilance; and quality assurance services. In addition, it develops, manufactures, and sells med...

• Industry: Commercial Physical and Biological Research
• Founded: 2003
• Employees: 160
• Stock Exchange: KOSDAQ
• Ticker Symbol: 187660

Financial Performance

In 2024, Hyundai ADM Bio's revenue was 9.74 billion, a decrease of -29.33% compared to the previous year's 13.79 billion. Losses were -20.10 billion, 576.6% more than in 2023.